The HCT 116-I6 cell line is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively compared to the parental cell line.
| Inventor | Institute |
|---|---|
| Sandra Van Schaeybroeck | Queen's University Belfast |
| SKU: | 153208 |
|---|---|
| Product description: | The HCT 116-I6 cell line is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively compared to the parental cell line. |
| Conditional: | No |
| Production details: | HCT 116 cells were incubated in a Matrigel Invasion Chambers (MIC) for 72-96h. The cells that invaded through to the bottom chamber were collected and designated as ÄË?Â?ÂInvasive 1ÄË?Â? (I1). These cells were propagated and repeatedly passed through the MIC until highly invasive HCT116-I6 cells were selected. |
| Cellosaurus ID: | CVCL_HG06 |
| Parental cell line: | HCT 116 |
| Disease: | Cancer |
| Cat. #: | 153208 |
|---|---|
| Provenance and Ownership: | The HCT 116-I6 Invasive Cell Line is owned by Cancer Research UK. CancerTools supplies the HCT 116-I6 Invasive Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing HCT 116-I6 Invasive Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Colorectal cancer |
| Research Fields: | Cancer; Cell biology; Drug development |
| Organism: | Human |
| Tissue: | Colon |
| Model: | Cancer Model |
| Growth properties: | Invasion, migration |
| Cancer Types In Detail: | Colorectal |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 ?g/ml streptomycin |
| References: |
Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.